“We are building upon deep cancer biology expertise to map, target and unlock tumor-specific epitopes which enable us to develop a pipeline of next-generation precision oncology therapeutics,” said Jeff Landau, Chief Executive Officer of Stipple Bio. “This funding positions us to progress STP-100 into the clinic and continue building a broad oncology pipeline. I am extremely pleased to have the support of industry-leading investors who share our enthusiasm towards developing precision and differentiated cancer therapies based on our modality-agnostic Pointillist Platform.”